prednisone has been researched along with Dancing Eyes-Dancing Feet Syndrome in 6 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eligible subjects were randomized to receive twelve cycles of IVIG (IVIG+) or no IVIG (NO-IVIG) in addition to prednisone and neuroblastoma risk-adapted chemotherapy." | 9.27 | Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. ( Cohn, SL; de Alarcon, PA; Hogarty, MD; London, WB; Maris, JM; Matthay, KK; Naranjo, A; Panzer, JA; Park, JR; Tenney, SC, 2018) |
| "Eligible subjects were randomized to receive twelve cycles of IVIG (IVIG+) or no IVIG (NO-IVIG) in addition to prednisone and neuroblastoma risk-adapted chemotherapy." | 5.27 | Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. ( Cohn, SL; de Alarcon, PA; Hogarty, MD; London, WB; Maris, JM; Matthay, KK; Naranjo, A; Panzer, JA; Park, JR; Tenney, SC, 2018) |
| "Kinsbourne syndrome or opsoclonus myoclonus syndrome (OMS) is characterized by rapid, involuntary, irregular conjugate eye movements (opsoclonus), myoclonic jerking of the limbs and trunk, ataxia, and behavioral disturbances." | 1.35 | Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up. ( Aarsen, FK; Catsman-Berrevoets, CE; Hakvoort-Cammel, FG; van den Heuvel-Eibrink, MM; van Hemsbergen, ML; van Noesel, MM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galstyan, A | 1 |
| Wilbur, C | 1 |
| Selby, K | 1 |
| Hukin, J | 1 |
| de Alarcon, PA | 1 |
| Matthay, KK | 1 |
| London, WB | 1 |
| Naranjo, A | 1 |
| Tenney, SC | 1 |
| Panzer, JA | 1 |
| Hogarty, MD | 1 |
| Park, JR | 1 |
| Maris, JM | 1 |
| Cohn, SL | 1 |
| Kushner, BH | 1 |
| Khakoo, Y | 1 |
| Scott, KM | 1 |
| Parker, F | 1 |
| Heckmann, JM | 1 |
| Catsman-Berrevoets, CE | 1 |
| Aarsen, FK | 1 |
| van Hemsbergen, ML | 1 |
| van Noesel, MM | 1 |
| Hakvoort-Cammel, FG | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| Battaglia, T | 1 |
| De Grandis, E | 1 |
| Mirabelli-Badenier, M | 1 |
| Boeri, L | 1 |
| Morcaldi, G | 1 |
| Barabino, P | 1 |
| Intra, C | 1 |
| Naselli, F | 1 |
| Pistoia, V | 1 |
| Veneselli, E | 1 |
| Conte, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone[NCT00033293] | Phase 3 | 53 participants (Actual) | Interventional | 2004-03-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Bayley Scales of infant development mental scale best score of two time points will be used in the analysis. For a given patient, this score will be used to calculate the change from baseline." (NCT00033293)
Timeframe: Changes from baseline to the better of 6 months or 1 year
| Intervention | Change in Bayley's score (Mean) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 117.5 |
| Arm II (Chemotherapy, Observation) | 100.75 |
"The best score at the two time points will be used in this analysis. For a given patient, this best score will be used to calculate the change from baseline. The mean change from baseline for each treatment group will be calculated." (NCT00033293)
Timeframe: Changes from baseline to the better of 6 months or 1 year
| Intervention | Change in VABS score (Mean) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 84.53 |
| Arm II (Chemotherapy, Observation) | 144.73 |
A multi-stage design followed by a test of proportions between the treatment arms (chemo vs. chemo + therapeutic immune globulin (IVIG)) will be performed. The first stage of the multi-stage design will also function as an early stopping rule for insufficient activity of chemotherapy in OMA. (NCT00033293)
Timeframe: Changes from baseline to 2 months, 6 months, and 1 year
| Intervention | participants (Number) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 21 |
| Arm II (Chemotherapy, Observation) | 11 |
EFS rate for neuroblastoma event from time of study enrollment. (NCT00033293)
Timeframe: Up to 3 years
| Intervention | 3 year EFS (Number) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 92.3 |
| Arm II (Chemotherapy, Observation) | 96.0 |
OS rate from time of study enrollment. (NCT00033293)
Timeframe: Up to 3 years
| Intervention | 3 year OS (Number) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 100 |
| Arm II (Chemotherapy, Observation) | 96.0 |
1 trial available for prednisone and Dancing Eyes-Dancing Feet Syndrome
| Article | Year |
|---|---|
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Child; Child, Pres | 2018 |
5 other studies available for prednisone and Dancing Eyes-Dancing Feet Syndrome
| Article | Year |
|---|---|
Opsoclonus-Myoclonus Syndrome: A New Era of Improved Prognosis?
Topics: Adrenal Cortex Hormones; Child, Preschool; Female; Humans; Immunoglobulins, Intravenous; Immunosuppr | 2017 |
Enigmatic entities: opsoclonus myoclonus ataxia syndrome linked to neuroblastoma.
Topics: Ataxia; Child; Humans; Immunoglobulins, Intravenous; Neuroblastoma; Opsoclonus-Myoclonus Syndrome; P | 2018 |
Opsoclonus-myoclonus syndrome and HIV-infection.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Autoi | 2009 |
Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up.
Topics: Adolescent; Adrenocorticotropic Hormone; Child; Child, Preschool; Cognition Disorders; Female; Follo | 2009 |
Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments.
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Ataxi | 2012 |